DK3474883T3 - Komplementinhibitorer og anvendelser deraf - Google Patents
Komplementinhibitorer og anvendelser deraf Download PDFInfo
- Publication number
- DK3474883T3 DK3474883T3 DK17736601.0T DK17736601T DK3474883T3 DK 3474883 T3 DK3474883 T3 DK 3474883T3 DK 17736601 T DK17736601 T DK 17736601T DK 3474883 T3 DK3474883 T3 DK 3474883T3
- Authority
- DK
- Denmark
- Prior art keywords
- complement inhibitors
- complement
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16176739 | 2016-06-28 | ||
PCT/EP2017/065979 WO2018002131A1 (en) | 2016-06-28 | 2017-06-28 | Complement inhibitors and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3474883T3 true DK3474883T3 (da) | 2022-08-29 |
Family
ID=56360183
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK17736601.0T DK3474883T3 (da) | 2016-06-28 | 2017-06-28 | Komplementinhibitorer og anvendelser deraf |
Country Status (13)
Country | Link |
---|---|
US (1) | US20190202878A1 (da) |
EP (1) | EP3474883B1 (da) |
JP (1) | JP7068203B2 (da) |
KR (1) | KR102566634B1 (da) |
CN (1) | CN109689084A (da) |
AU (1) | AU2017289214B2 (da) |
CA (1) | CA3029106A1 (da) |
DK (1) | DK3474883T3 (da) |
ES (1) | ES2925466T3 (da) |
IL (1) | IL263949A (da) |
MX (1) | MX2019000059A (da) |
PL (1) | PL3474883T3 (da) |
WO (1) | WO2018002131A1 (da) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201800620D0 (en) * | 2018-01-15 | 2018-02-28 | Univ Manchester | C3b Binding Polypeptide |
AU2019367965A1 (en) * | 2018-10-22 | 2021-06-03 | Icellkealex Therapeutics Llc | Mutant vaccinia viruses and use thereof |
AU2020313981A1 (en) * | 2019-07-17 | 2022-03-03 | Gemini Therapeutics Sub, Inc. | Factor H potentiating antibodies and uses thereof |
IL299048A (en) | 2020-06-14 | 2023-02-01 | Vertex Pharma | Variants of complement factor - 1 fusion structures and preparations containing them and their uses |
GB202203627D0 (en) | 2022-03-16 | 2022-04-27 | Univ Manchester | Agents for treating complement-related disorders |
WO2023197930A1 (zh) * | 2022-04-11 | 2023-10-19 | 天辰生物医药(苏州)有限公司 | 补体抑制杂合蛋白 |
CN118005802A (zh) * | 2022-11-10 | 2024-05-10 | 天辰生物医药(苏州)有限公司 | 补体抑制杂合蛋白突变体及其抗体融合蛋白 |
WO2024146953A1 (en) | 2023-01-05 | 2024-07-11 | Complement Therapeutics Limited | Agents and methods for treating complement diseases |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0512733A2 (en) * | 1991-05-03 | 1992-11-11 | Washington University | Modified complement system regulator |
US8124097B2 (en) * | 2004-01-21 | 2012-02-28 | Case Western Reserve University | Hybrid and chimeric polypeptides that regulate activation of complement |
US8937046B2 (en) * | 2008-09-22 | 2015-01-20 | The Regents Of The University Of Colorado, A Body Corporate | Modulating the alternative complement pathway |
US9540626B2 (en) | 2012-03-19 | 2017-01-10 | The Trustees Of The University Of Pennsylvania | Regulator of complement activation and uses thereof |
-
2017
- 2017-06-28 JP JP2018567848A patent/JP7068203B2/ja active Active
- 2017-06-28 WO PCT/EP2017/065979 patent/WO2018002131A1/en unknown
- 2017-06-28 US US16/311,711 patent/US20190202878A1/en active Pending
- 2017-06-28 CA CA3029106A patent/CA3029106A1/en active Pending
- 2017-06-28 KR KR1020197002195A patent/KR102566634B1/ko active IP Right Grant
- 2017-06-28 CN CN201780040882.6A patent/CN109689084A/zh active Pending
- 2017-06-28 DK DK17736601.0T patent/DK3474883T3/da active
- 2017-06-28 ES ES17736601T patent/ES2925466T3/es active Active
- 2017-06-28 EP EP17736601.0A patent/EP3474883B1/en active Active
- 2017-06-28 MX MX2019000059A patent/MX2019000059A/es unknown
- 2017-06-28 PL PL17736601.0T patent/PL3474883T3/pl unknown
- 2017-06-28 AU AU2017289214A patent/AU2017289214B2/en active Active
-
2018
- 2018-12-24 IL IL263949A patent/IL263949A/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP7068203B2 (ja) | 2022-05-16 |
ES2925466T3 (es) | 2022-10-18 |
US20190202878A1 (en) | 2019-07-04 |
CN109689084A (zh) | 2019-04-26 |
EP3474883B1 (en) | 2022-05-25 |
CA3029106A1 (en) | 2018-01-04 |
AU2017289214B2 (en) | 2021-11-18 |
KR102566634B1 (ko) | 2023-08-14 |
EP3474883A1 (en) | 2019-05-01 |
IL263949A (en) | 2019-01-31 |
JP2019523238A (ja) | 2019-08-22 |
AU2017289214A1 (en) | 2019-01-24 |
PL3474883T3 (pl) | 2022-09-19 |
WO2018002131A1 (en) | 2018-01-04 |
MX2019000059A (es) | 2020-09-07 |
KR20190039090A (ko) | 2019-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3658557T3 (da) | Tyk2-inhibitorer og anvendelser deraf | |
DK3389658T3 (da) | Glycosidasehæmmere og anvendelser deraf | |
DK3448386T3 (da) | Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf | |
DK3888658T3 (da) | Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil | |
DK3452463T3 (da) | Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf | |
DK3442972T3 (da) | Bromdomænehæmmere | |
DK3521289T3 (da) | Mnk-inhibitorer og fremgangsmåder forbundet dermed | |
DK3189081T3 (da) | Cd123-bindende midler og anvendelser deraf | |
DK3193611T3 (da) | Mk2-inhibitorer og anvendelser deraf | |
DK3610005T3 (da) | Peptidligase og anvendelse deraf | |
DK3218358T3 (da) | Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner | |
DK3227237T3 (da) | Indretning og anvendelse deraf til uv-bearbejdning af fluider | |
DK3621694T5 (da) | Lrrc33-inhibitorer og anvendelse heraf | |
DK3474883T3 (da) | Komplementinhibitorer og anvendelser deraf | |
DK3571192T3 (da) | Jak1-selektive inhibitorer | |
DK3543240T3 (da) | URAT1-inhibitor og anvendelse deraf | |
DK3209773T3 (da) | Prolintolerante tripeptidylpeptidaser og anvendelser deraf | |
DK3532459T3 (da) | Lsd1-hæmmere og medicinske anvendelser deraf | |
DK3630744T3 (da) | Pyrazol-magl-inhibitorer | |
DK3265641T3 (da) | Stigørenhed og fremgangsmåde | |
DK3161139T3 (da) | Tlr-4-specifikke aptamerer og anvendelser heraf | |
DK3426243T3 (da) | 3-phosphoglyceratdehydrogenase-inhibitorer og anvendelser deraf | |
DK3128005T3 (da) | Sirp-alfa-variantkonstruktioner og anvendelser deraf | |
DK3516160T3 (da) | Brøndanordning og tilhørende fremgangsmåder | |
DK3142659T3 (da) | Hiv-1 proteasehæmmere og anvendelser deraf |